home > news > detailed info

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine


VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.

"The THEVAX HBV vaccine has been developed employing our company patented technology platform, which has enabled us to proceed from process development into cGMP production in a much shorter period of time. We are pleased to partner with Biotechpharma as our CDMO for cGMP manufacturing of our molecule entering clinical trials. Biotechpharma's excellent track record, expertise and capabilities to timely deliver a high quality product will play a significant role in the success of this program," says KinKai (Ben) Hwang, CSO of TheVax Genetics Vaccine CO., Ltd.

"We are delighted to be working with TheVax Genetics Vaccine CO on this exciting project and with great enthusiasm look forward to seeing it enter clinical trials," comments Vladas Bumelis, CEO of Biotechpharma. "Biotechpharma is well positioned to facilitate successful process transfer and manufacture of HBV vaccine in rapid time-frames, with focus on high quality and excellence in service."

About TheVax Genetics Vaccine CO., Ltd

TheVax Genetics Vaccine CO. Ltd is a publicly traded Taiwan-based company engaged in development of human vaccines. The Company's main products include therapeutic monovalent vaccines TVGV-1 and multivalent vaccines TVGV-2 for treatment of cervical cancer and precancerous lesions, and therapeutic vaccines TVGV-HBV for treatment of Hepatitis B.

About Biotechpharma UAB

Biotechpharma UAB is a leading biopharmaceutical CDMO providing fully integrated process development and GMP manufacturing services globally. Biotechpharma has extensive experience in the production of new biological entities, having 150 employees at its state-of-the-art facility in Vilnius, Lithuania.

Related Links
email Mokslininku st. 4. LT-08412 Vilnius, Lithuania
Print this page
Send to a friend
News and Press Releases

Porton Biopharma opens new facility to make more of its childhood cancer cure

In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.   
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

Industry Events

Automatica 2018

18 June 2018, Messe München, Munich, Germany

Automatica is the leading exhibition for smart automation and robotics. It features the world's largest range of robotics, assembly systems, machine vision systems and components. For more information go to
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement